1. Generics Bulletin
  2. >>Leadership

People Round-Up: All Change At UK Agencies As Brexit Looms

 
• By Aidan Fry

The head of the UK’s health technology assessment body NICE is stepping down, while the country’s medicines agency, the MHRA, will have an interim chief in the run-up to the UK’s planned Brexit from the European Union on 31 October.

People
Changes in leadership are planned at the UK's NICE and MHRA authorities • Source: Shutterstock

Sir Andrew Dillon will next year step down as chief executive of England’s health technology assessment body, the National Institute for Health and Care Excellence, after more than 20 years in the role. NICE’s board plans to start advertising for a replacement later this year.

Having led the body since its inception in April 1999, Dillon will leave his post at the end of March 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.